Clover Biopharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	380.94	401.24	735.86	1,607	2,767	516.18
Short-Term Investments	-	-	2.94	2.94	61.09	270.33
Trading Asset Securities	14.8	14.78	14.17	13.93	30.91	-
Cash & Short-Term Investments	395.74	416.02	752.97	1,624	2,859	786.51
Cash Growth	-17.72%	-44.75%	-53.64%	-43.19%	263.55%	395.62%
Accounts Receivable	2.16	40.99	24.11	-	-	-
Other Receivables	-	24.21	49.6	-	-	-
Receivables	2.16	65.21	73.71	-	-	-
Inventory	11.76	11.03	696.98	2,384	768.69	50.88
Restricted Cash	9.7	11.5	13.29	16.3	6.8	20
Other Current Assets	40.43	159.44	362.58	365.01	1,442	191.03
Total Current Assets	459.79	663.21	1,900	4,390	5,076	1,048
Property, Plant & Equipment	103.99	116.18	162.06	241.74	222.4	86.99
Other Intangible Assets	30.43	33.35	39.86	35	13.83	0.28
Other Long-Term Assets	-	-	-	28.04	32.93	51.84
Total Assets	594.21	812.74	2,101	4,695	5,346	1,188
Accounts Payable	111.15	120.45	247.83	856.96	588.56	34.76
Accrued Expenses	-	42.26	70.62	88.47	96.9	25.69
Short-Term Debt	-	73.97	308.06	294.06	-	-
Current Portion of Leases	11.99	12.18	18.54	23.57	21.48	4.26
Current Unearned Revenue	1,588	1,612	1,578	1,555	1,424	-
Other Current Liabilities	52.55	46.35	54.11	10.84	17.62	2.03
Total Current Liabilities	1,764	1,908	2,277	2,829	2,148	66.73
Long-Term Debt	-	-	-	-	-	1,127
Long-Term Leases	1.06	3.5	7.85	36.74	46.44	18.06
Long-Term Unearned Revenue	25.3	25.3	44.36	2,497	1,932	958.17
Other Long-Term Liabilities	510.46	512.58	505.05	-	-	-
Total Liabilities	2,300	2,449	2,834	5,363	4,127	2,170
Common Stock	0.84	0.84	0.84	0.84	0.74	-
Additional Paid-In Capital	8,659	8,654	8,621	8,562	7,972	-
Retained Earnings	-10,645	-10,544	-9,640	-9,502	-7,050	-1,034
Treasury Stock	-0.02	-0.03	-0.03	-0.04	-0.05	-
Comprehensive Income & Other	278.59	252.84	285.85	270.38	296.63	50.78
Shareholders' Equity	-1,706	-1,636	-732.83	-668.14	1,219	-982.74
Total Liabilities & Equity	594.21	812.74	2,101	4,695	5,346	1,188
Total Debt	13.05	89.64	334.45	354.37	67.92	1,150
Net Cash (Debt)	382.7	326.38	418.52	1,270	2,791	-363.11
Net Cash Growth	53.16%	-22.02%	-67.04%	-54.51%	-	-
Net Cash Per Share	0.30	0.26	0.34	1.15	2.41	-0.48
Filing Date Shares Outstanding	1,297	1,297	1,296	1,293	1,158	1,158
Total Common Shares Outstanding	1,297	1,297	1,296	1,293	1,158	-
Working Capital	-1,304	-1,244	-377.48	1,561	2,928	981.69
Book Value Per Share	-1.32	-1.26	-0.57	-0.52	1.05	-
Tangible Book Value	-1,737	-1,670	-772.69	-703.14	1,205	-983.02
Tangible Book Value Per Share	-1.34	-1.29	-0.60	-0.54	1.04	-
Buildings	-	-	29.8	29.75	29.75	-
Machinery	-	-	147.25	128.37	101.65	28.48
Construction In Progress	-	-	25.28	44.08	32.15	38.29
Leasehold Improvements	-	-	35.79	31.6	11.38	6.06

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.